Retro Bio Begins First-in-Human Longevity Study

Clinical innovation is moving faster than ever. From streamlined approvals to smarter data and global collaboration, early-phase research is transforming how new therapies reach patients.

first-in-human · FDA · data

Clinical innovation is moving faster than ever. From streamlined approvals to smarter data and global collaboration, early-phase research is transforming how new therapies reach patients.

Emerging-market efficiency is redefining trial timelines. Argentina proves cost-effectiveness fuels faster outcomes. Omeros earns its first FDA nod in rare-disease therapy. Retro Bio moves longevity science from lab to clinic. Flow Neuroscience reimagines depression care at home.

Innovation is accelerating — stay ahead of the curve. 👇

← All Global Trial Accelerators editions · Contact bioaccess®